These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2735191)

  • 1. Membrane abnormality in malignant hyperthermia.
    Shah A; Sahgal V; Subramani V
    Acta Neuropathol; 1989; 78(1):86-9. PubMed ID: 2735191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Wappler F; Scholz J; Fiege M; Richter A; Steinfath M; Weisshorn R; Schulte am Esch J
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Oct; 360(4):376-81. PubMed ID: 10551274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs.
    Iaizzo PA; Klein W; Lehmann-Horn F
    Pflugers Arch; 1988 Jun; 411(6):648-53. PubMed ID: 3412868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluidity state of lymphocyte plasma membrane in malignant hyperthermia susceptible pigs and humans.
    Rock E; Motta C; Vignon X; Kozak-Ribbens G
    Acta Anaesthesiol Scand; 1993 Jul; 37(5):488-92. PubMed ID: 8356862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle.
    Glover L; Heffron JJ; Ohlendieck K
    J Appl Physiol (1985); 2004 Jan; 96(1):11-8. PubMed ID: 12959958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and biochemical defects in muscles of human carriers of the malignant hyperthermia syndrome.
    Isaacs H; Heffron JJ
    Br J Anaesth; 1975 Apr; 47(4):475-81. PubMed ID: 124580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia.
    Isaacs H; Badenhorst M
    Anesthesiology; 1993 Jul; 79(1):5-9. PubMed ID: 8342829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
    Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
    Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Histological, histochemical, and ultrastructural findings in malignant hyperthermia (author's transl)].
    Gullotta F; Helpap B
    Virchows Arch A Pathol Anat Histol; 1975 Aug; 367(3):181-94. PubMed ID: 808899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total calcium content of skeletal muscle isolated from humans and pigs susceptible to malignant hyperthermia.
    Britt BA; Endrenyi L; Barclay RL; Cadman DL
    Br J Anaesth; 1975 Jun; 47(6):647-53. PubMed ID: 1148084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volatile anesthetics inhibit dihydropyridine binding to malignant hyperthermia-susceptible and normal pig skeletal muscle membranes.
    Louis CF; Roghair T; Mickelson JR
    Anesthesiology; 1994 Mar; 80(3):618-24. PubMed ID: 8141457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Porcine malignant hyperthermia susceptibility: hypersensitive calcium-release mechanism of skeletal muscle sarcoplasmic reticulum.
    O'Brien PJ
    Can J Vet Res; 1986 Jul; 50(3):318-28. PubMed ID: 3742367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Examination of the family of a patient susceptible to anesthetic malignant hyperthermia].
    Krivosic-Horber R; Theunynck D; Krivosic I; Adnet P; Guévart E
    Ann Fr Anesth Reanim; 1986; 5(3):326-9. PubMed ID: 3777561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial and plasma membrane changes in skeletal muscle in the malignant hyperthermia syndrome.
    Heffron JJ
    Biochem Soc Trans; 1984 Jun; 12(3):360-2. PubMed ID: 6734894
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Picture frame' fibres in a carrier of the trait for malignant hyperpyrexia.
    Isaacs H; Heffron JJ; Badenhorst M
    S Afr Med J; 1975 Nov; 49(46):1923-6. PubMed ID: 795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of propofol on Ca2+ regulation by malignant hyperthermia-susceptible muscle membranes.
    Fruen BR; Mickelson JR; Roghair TJ; Litterer LA; Louis CF
    Anesthesiology; 1995 May; 82(5):1274-82. PubMed ID: 7741303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle.
    Anderson IL; Jones EW
    Anesthesiology; 1976 Jan; 44(1):57-61. PubMed ID: 1244776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
    Nelson TE; Bedell DM; Jones EW
    Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.